Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification

Hidekazu Suzuki, Toshihiro Nishizawa, Toshifumi Hibi

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Although placebo response rates in clinical trials for functional dyspepsia (FD) are more than 30%, a recent meta-analysis based on randomized controlled trials (RCTs) showed that antisecretory drugs were more or less superior to placebos. On the other hand, large-scale RCTs on the efficacy of treatment with prokinetics on FD are still needed. Indications for antibiotic eradication therapy for Helicobacter pylori-positive FD are still controversial, but there seems to be a small but significant therapeutic gain achieved with H. pylori eradication. Since preprandial and postprandial symptomatic disturbances are very important targets for FD treatment, ghrelin, a novel appetite-promoting gastrointestinal peptide that also promotes gastric motility or basal acid secretion can be expected to be a therapeutic target. In the recently published Rome III classification, FD is redefined for patients with symptoms thought to originate from the gastroduodenal region, specifically epigastric pain or burning, postprandial fullness, or early satiation, and it is divided into the subcategories postprandial distress syndrome and epigastric pain syndrome. These new criteria are of value in clinical practice, for epidemiological, pathophysiological, and clinical research, and for the development of new therapeutic strategies.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalJournal of Gastroenterology
Volume41
Issue number6
DOIs
Publication statusPublished - 2006 Jun

Fingerprint

Dyspepsia
Helicobacter pylori
Randomized Controlled Trials
Placebos
Satiation
Therapeutics
Pain
Ghrelin
Appetite
Meta-Analysis
Stomach
Clinical Trials
Anti-Bacterial Agents
Peptides
Acids
Research
Pharmaceutical Preparations

Keywords

  • Epigastric pain syndrome (EPS)
  • Ghrelin
  • Placebo
  • Postprandial distress syndrome (PDS)
  • Prokinetics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. / Suzuki, Hidekazu; Nishizawa, Toshihiro; Hibi, Toshifumi.

In: Journal of Gastroenterology, Vol. 41, No. 6, 06.2006, p. 513-523.

Research output: Contribution to journalArticle

Suzuki, Hidekazu ; Nishizawa, Toshihiro ; Hibi, Toshifumi. / Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. In: Journal of Gastroenterology. 2006 ; Vol. 41, No. 6. pp. 513-523.
@article{c5e7d73e517a42d1a5885a14f7d7633e,
title = "Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification",
abstract = "Although placebo response rates in clinical trials for functional dyspepsia (FD) are more than 30{\%}, a recent meta-analysis based on randomized controlled trials (RCTs) showed that antisecretory drugs were more or less superior to placebos. On the other hand, large-scale RCTs on the efficacy of treatment with prokinetics on FD are still needed. Indications for antibiotic eradication therapy for Helicobacter pylori-positive FD are still controversial, but there seems to be a small but significant therapeutic gain achieved with H. pylori eradication. Since preprandial and postprandial symptomatic disturbances are very important targets for FD treatment, ghrelin, a novel appetite-promoting gastrointestinal peptide that also promotes gastric motility or basal acid secretion can be expected to be a therapeutic target. In the recently published Rome III classification, FD is redefined for patients with symptoms thought to originate from the gastroduodenal region, specifically epigastric pain or burning, postprandial fullness, or early satiation, and it is divided into the subcategories postprandial distress syndrome and epigastric pain syndrome. These new criteria are of value in clinical practice, for epidemiological, pathophysiological, and clinical research, and for the development of new therapeutic strategies.",
keywords = "Epigastric pain syndrome (EPS), Ghrelin, Placebo, Postprandial distress syndrome (PDS), Prokinetics",
author = "Hidekazu Suzuki and Toshihiro Nishizawa and Toshifumi Hibi",
year = "2006",
month = "6",
doi = "10.1007/s00535-006-1847-5",
language = "English",
volume = "41",
pages = "513--523",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification

AU - Suzuki, Hidekazu

AU - Nishizawa, Toshihiro

AU - Hibi, Toshifumi

PY - 2006/6

Y1 - 2006/6

N2 - Although placebo response rates in clinical trials for functional dyspepsia (FD) are more than 30%, a recent meta-analysis based on randomized controlled trials (RCTs) showed that antisecretory drugs were more or less superior to placebos. On the other hand, large-scale RCTs on the efficacy of treatment with prokinetics on FD are still needed. Indications for antibiotic eradication therapy for Helicobacter pylori-positive FD are still controversial, but there seems to be a small but significant therapeutic gain achieved with H. pylori eradication. Since preprandial and postprandial symptomatic disturbances are very important targets for FD treatment, ghrelin, a novel appetite-promoting gastrointestinal peptide that also promotes gastric motility or basal acid secretion can be expected to be a therapeutic target. In the recently published Rome III classification, FD is redefined for patients with symptoms thought to originate from the gastroduodenal region, specifically epigastric pain or burning, postprandial fullness, or early satiation, and it is divided into the subcategories postprandial distress syndrome and epigastric pain syndrome. These new criteria are of value in clinical practice, for epidemiological, pathophysiological, and clinical research, and for the development of new therapeutic strategies.

AB - Although placebo response rates in clinical trials for functional dyspepsia (FD) are more than 30%, a recent meta-analysis based on randomized controlled trials (RCTs) showed that antisecretory drugs were more or less superior to placebos. On the other hand, large-scale RCTs on the efficacy of treatment with prokinetics on FD are still needed. Indications for antibiotic eradication therapy for Helicobacter pylori-positive FD are still controversial, but there seems to be a small but significant therapeutic gain achieved with H. pylori eradication. Since preprandial and postprandial symptomatic disturbances are very important targets for FD treatment, ghrelin, a novel appetite-promoting gastrointestinal peptide that also promotes gastric motility or basal acid secretion can be expected to be a therapeutic target. In the recently published Rome III classification, FD is redefined for patients with symptoms thought to originate from the gastroduodenal region, specifically epigastric pain or burning, postprandial fullness, or early satiation, and it is divided into the subcategories postprandial distress syndrome and epigastric pain syndrome. These new criteria are of value in clinical practice, for epidemiological, pathophysiological, and clinical research, and for the development of new therapeutic strategies.

KW - Epigastric pain syndrome (EPS)

KW - Ghrelin

KW - Placebo

KW - Postprandial distress syndrome (PDS)

KW - Prokinetics

UR - http://www.scopus.com/inward/record.url?scp=33746531713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746531713&partnerID=8YFLogxK

U2 - 10.1007/s00535-006-1847-5

DO - 10.1007/s00535-006-1847-5

M3 - Article

C2 - 16868798

AN - SCOPUS:33746531713

VL - 41

SP - 513

EP - 523

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 6

ER -